Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in the human respiratory tract

This article has been Reviewed by the following groups

Read the full article

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2020.04.22.056127: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: Ethics: Studies on human tissues were approved by the institutional review board of the University of Iowa (Iowa IRB #199507432).
    Consent: Informed consent was obtained for all the tissues included in the study.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variable(15 chronic comorbidities and 14 controls) with a broad range of ages (0·5 – 71 years) and both sexes were represented (13 female and 16 male).

    Table 2: Resources

    Antibodies
    SentencesResources
    Primary antibodies anti-ACE2 (1:100
    anti-ACE2
    suggested: (Enzo Life Sciences Cat# ALX-804-722-C100, RRID:AB_11180102)
    Secondary antibodies anti-mouse Alexa568 (for ACE2) and anti-rabbit Alexa488 (for TMPRSS2) were applied at a concentration of 1:600 for 1 hour at room temperature.
    anti-mouse
    suggested: (Bioss Cat# bsm-4579M-Alexa488, RRID:AB_11071160)
    anti-rabbit
    suggested: None
    TMPRSS2
    suggested: None
    Software and Algorithms
    SentencesResources
    Analysis of single cell RNA sequencing data: Single cell RNA sequencing data sets were accessed from Gene Expression Omnibus (GEO) series GSE121600 (27) and GSE122960 (26).
    Gene Expression Omnibus
    suggested: (Gene Expression Omnibus (GEO, RRID:SCR_005012)
    All analyses were performed using R package Seurat version 3.1.1 (34).
    Seurat
    suggested: (SEURAT, RRID:SCR_007322)
    Statistical analyses: Statistical analyses for group comparisons and tissue scoring data were performed using GraphPad Prism version 8 (GraphPad Software, La Jolla, CA USA).
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.